ImageneBio holders approve amended equity plan
ImageneBio, Inc. reported the results of its 2026 Annual Meeting of Stockholders.
Rhea-AI Filing Summary
ImageneBio, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amended and restated 2025 Equity Incentive Plan that increases the shares of common stock authorized for issuance under the plan by 850,000 shares and adjusts how the automatic annual share reserve increase is calculated.
They also elected two Class II directors, David P. Bonita, M.D. and Joseph P. Slattery, to serve until the 2029 annual meeting, and ratified PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026. There were 11,279,130 shares of voting common stock outstanding as of the April 28, 2026 record date.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Equity plan share increase: 850,000 shares
Shares outstanding: 11,279,130 shares
Director vote – Bonita For: 6,980,671 shares
+3 more
6 metrics
Equity plan share increase
850,000 shares
Additional common stock authorized under Amended 2025 Equity Incentive Plan
Shares outstanding
11,279,130 shares
Voting common stock outstanding as of April 28, 2026 record date
Director vote – Bonita For
6,980,671 shares
Votes for election of David P. Bonita, M.D. as Class II director
Director vote – Slattery For
6,985,414 shares
Votes for election of Joseph P. Slattery as Class II director
Auditor ratification For
7,613,075 shares
Votes for ratifying PricewaterhouseCoopers LLP for FY ending December 31, 2026
Equity plan approval For
6,322,909 shares
Votes for approving the Amended and Restated 2025 Equity Incentive Plan
Key Terms
Equity Incentive Plan, Broker Non-Votes, independent registered public accounting firm, emerging growth company, +1 more
5 terms
Equity Incentive Plan financial
"increase the aggregate number of shares of common stock authorized for issuance under the 2025 Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Broker Non-Votes financial
"The final voting results are as follows ... Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the appointment ... as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
emerging growth company regulatory
"Emerging growth company (e) On June 16, 2026, ImageneBio, Inc."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ImageneBio (IMA) announce from its 2026 Annual Meeting?
ImageneBio reported that stockholders approved changes to its 2025 Equity Incentive Plan, re-elected two Class II directors, and ratified PricewaterhouseCoopers LLP as independent auditor for 2026. These items reflect routine governance and compensation approvals decided by shareholder vote.
Who was elected to ImageneBio (IMA)’s board at the 2026 Annual Meeting?
Stockholders elected David P. Bonita, M.D. and Joseph P. Slattery as Class II directors. They will serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until earlier death, resignation, or removal under the company’s governance rules.
What were the voting results for ImageneBio’s Amended 2025 Equity Incentive Plan?
The Amended 2025 Equity Incentive Plan received 6,322,909 votes for, 591,191 against, and 106,688 abstentions, with 612,769 broker non-votes. This outcome shows stockholder approval of the plan’s increased share authorization and changes to the automatic annual share reserve calculation.
Which audit firm did ImageneBio (IMA) stockholders ratify for 2026?
Stockholders ratified PricewaterhouseCoopers LLP as ImageneBio’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification vote totaled 7,613,075 shares for, 20,477 against, and 5 abstentions, confirming continued engagement of the same audit firm.
AI-generated analysis. How Rhea-AI works. Not financial advice.
